UK's Ranier gets £8m for spinal implants:
This article was originally published in Clinica
Ranier Technology has secured £8m ($16m) in new capital to fund the development and commercialisation of its motion-preserving spinal implants. Participating in the financing round were new investor Alliance Trust Equity Partners and existing shareholder First Ventures. Cambridge, UK-based Ranier will use the proceeds for the clinical trials and European launch of CAdisc L, a replacement spinal disc for the lumbar region, as well as for the development of CAdisc C, a cervical version of the product.
You may also be interested in...
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.